MedImmune

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, MedImmune sits in the top decile of US sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count).

210 total trials none currently recruiting 185 completed early-phase tilt top decile by trial count

MedImmune: 210 sponsored US clinical trials, none currently recruiting.

MedImmune sponsors 210 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 185 completed. 27 of these trials are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 9 trials.

Top-decile sponsor footprint

MedImmune ranks in the top decile of sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 68/100

185 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

How the MedImmune early-phase archive is shaped

210 indexed studies, none listed as recruiting (0% open); 185 completed (88%).

Phase mix: 27 late (III/IV) vs 164 early (I/II) (early-phase heavy).

Top condition: Healthy (9 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

MedImmune: archived-pipeline peers nationwide

Peers matched on 210 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

MedImmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200250 0%5%10%15%20%25% Total trials Recruiting share MedImmuneOHSU Knight Cancer InstituteUniversity of LouisvilleNational Center for Complementary and Integrative Health (NCCIH)The University of Texas Medical Branch, Galveston10xBio22nd Century Group23andMe3-C Institute for Social Development
MedImmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

MedImmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 210 archived trials

Sponsors with similar archive density (± trial count)

What to do with this MedImmune page

210 registered trials is a research-attention snapshot, not an endorsement of MedImmune or any single study.

  • None of MedImmune's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition MedImmune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. MedImmune pipeline card: 210 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.